PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Monday, August 14, 2023: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the second quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q2 2023
2023 2022 2023 2022 2022
TSEK April-June April-June Jan-June Jan-June Jan-Dec
Profit/loss
Other income 2.456 1.409 7.771 2.726 5.183
Profit/loss before -8.038 -7.963 -13.067 -12.981 -34.129
depreciation (EBITDA
Operating profit/loss -8.038 -7.963 -13.067 -12.981 -34.129
befor net financials
Net financials 7 3 9 6 81
Netprofit/loss for -8.031 -7.960 -13.058 -12.975 -34.048
the period
Earnings per share -0,19 -0,28 -0,31 -0,46 -1,09
(SEK)
- March 29, Biosergen provides Phase 2 clinical development strategy update.
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
The Financial report can be found on our website: https://biosergen.net/investors/filings